Have a personal or library account? Click to login
Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis Cover

Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis

Open Access
|Mar 2024

References

  1. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660
  2. W. D. Travis, E. Brambilla and G. J. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, J. Clin. Oncol. 31(8) (2013) 992–1001; https://doi.org/10.1200/jco.2012.46.9270
  3. A. T. Fathi and J. R. Brahmer, Chemotherapy for advanced stage non-small cell lung cancer, Semin. Thorac. Cardiovasc. Surg. 20(3) (2008) 210–216; https://doi.org/10.1053/j.semtcvs.2008.09.002
  4. A. Díaz-Serrano, P. Gella, E. Jiménez, J. Zugazagoitia and L. Paz-Ares Rodríguez, Targeting EGFR in lung cancer: Current standards and developments, Drugs 78(9) (2018) 893–911; https://doi.org/10.1007/s40265-018-0916-4
  5. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita and T. Nukiwa, Gefitinib or chemo-therapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362(25) (2010) 2380–2388; https://doi.org/10.1056/NEJMoa0909530
  6. M. Reck, D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rang-wala and J. R. Brahmer, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med. 375(19) (2016) 1823–1833; https://doi.org/10.1056/NEJMoa1606774
  7. J. Xie, J. Liu, H. Liu, S. Liang, M. Lin, Y. Gu, T. Liu, D. Wang, H. Ge and S. L. Mo, The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line, Acta Pharm. Sin. B. 5(6) (2015) 554–563; https://doi.org/10.1016/j.apsb.2015.07.008
  8. H. Luo, C. T. Vong, H. Chen, Y. Gao, P. Lyu, L. Qiu, M. Zhao, Q. Liu, Z. Cheng, J. Zou, P. Yao, C. Gao, J. Wei, C. O. L. Ung, S. Wang, Z. Zhong and Y. Wang, Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine, Chin. Med. 14 (2019) Article ID 48 (58 pages); https://doi.org/10.1186/s13020-019-0270-9
  9. M. Kluska and K. Woźniak, Natural polyphenols as modulators of etoposide anti-cancer activity, Int. J. Mol. Sci. 22(12) (2021) Article ID 6602 (16 pages); https://doi.org/10.3390/ijms22126602
  10. J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. Zhang, L. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He and L. Wang, Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial, Ann. Oncol. 28(4) (2017) 777–783; https://doi.org/10.1093/annonc/mdx009
  11. Y. Yoneshima, S. Morita, M. Ando, A. Nakamura, S. Iwasawa, H. Yoshioka, Y. Goto, M. Takeshita, T. Harada, K. Hirano, T. Oguri, M. Kondo, S. Miura, Y. Hosomi, T. Kato, T. Kubo, J. Kishimoto, N. Yamamoto, Y. Nakanishi and I. Okamoto, Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC, J. Thorac. Oncol. 16(9) (2021) 1523–1532; https://doi.org/10.1016/j.jtho.2021.03.027
  12. X. Jiang, W. Zhao, F. Zhu, H. Wu, X. Ding, J. Bai, X. Zhang and M. Qian, Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism, Toxicol. Appl. Pharmacol. 410 (2021) Article ID 115336 (25 pages); https://doi.org/10.1016/j.taap.2020.115336
  13. J. Zou, Y. Yang, Y. Yang and X. Liu, Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway, Biomed. Pharmacother. 108 (2018) 130–136; https://doi.org/10.1016/j.biopha.2018.09.051
  14. A. Ashaq, M. F. Maqbool, A. Maryam, M. Khan, H. A. Shakir, M. Irfan, J. I. Qazi, Y. Li and T. Ma, Hispidulin: A novel natural compound with therapeutic potential against human cancers, Phytother. Res. 35(2) (2021) 771–789; https://doi.org/10.1002/ptr.6862
  15. K. S. Prabhu, A. A. Bhat, K. S. Siveen, S. Kuttikrishnan, S. S. Raza, T. Raheed, A. Jochebeth, A. Q. Khan, M. Z. Chawdhery, M. Haris, M. Kulinski, S. Dermime, M. Steinhoff and S. Uddin, Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway, Biomed. Pharmacother. 144 (2021) Article ID 112358 (11 pages); https://doi.org/10.1016/j.biopha.2021.112358
  16. Y. Chen, L. Yin, M. Hao, W. Xu, J. Gao, Y. Sun, Q. Wang, S. Chen, Y. Liang, R. Guo, J. Zhang, J. Li, Q. Zhai, R. Cheng, J. Wang, H. Wang and Z. Yang, Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells, Acta Pharm. 73(2) (2023) 211–225; https://doi.org/10.2478/acph-2023-0016
  17. J. H. Kim, D. M. Kang, Y. J. Cho, J. W. Hyun and M. J. Ahn, Medicarpin increases antioxidant genes by inducing NRF2 transcriptional level in HeLa cells, Antioxidants (Basel) 11(2) (2022) Article ID 421 (10 pages); https://doi.org/10.3390/antiox11020421
  18. B. Bhargavan, D. Singh, A. K. Gautam, J. S. Mishra, A. Kumar, A. Goel, M. Dixit, R. Pandey, L. Manic-kavasagam, S. D. Dwivedi, B. Chakravarti, G. K. Jain, R. Ramachandran, R. Maurya, A. Trivedi, N. Chattopadhyay and S. Sanyal, Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin, J. Nutr. Biochem. 23(1) (2012) 27–38; https://doi.org/10.1016/j.jnutbio.2010.11.002
  19. A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and D. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice, Mol. Cell. Endocrinol. 325(1–2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016
  20. G. Gatouillat, A. A. Magid, E. Bertin, H. El btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells, Phytomedicine 22(13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005
  21. R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROSJNK-CHOP pathway, Cell Death Dis. 5(10) (2014) e1465; https://doi.org/10.1038/cddis.2014.429
  22. A. K. Yiğin, H. Donmez, M. Hitit, S. Seven, N. Eser, E. Kurar and M. Seven, The effect of medicarpin on PTEN/AKT signal pathway in head and neck squamous cell carcinoma, J. Cancer Res. Ther. 18(1) (2022) 180–184; https://doi.org/10.4103/jcrt.jcrt_641_21
  23. A. Mohr, L. Deedigan, S. Jencz, Y. Mehrabadi, L. Houlden, S. M. Albarenque and R. M. Zwacka, Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment, Cell Death Differ. 25(2) (2018) 340–352; https://doi.org/10.1038/cdd.2017.164
  24. H. S. Chin, M. X. Li, I. K. L. Tan, R. L. Ninnis, B. Reljic, K. Scicluna, L. F. Dagley, J. J. Sandow, G. L. Kelly, A. L. Samson, S. Chappaz, S. L. Khaw, C. Chang, A. Morokoff, K. Brinkmann, A. Webb, C. Hockings, C. M. Hall, A. J. Kueh, M. T. Ryan, R. M. Kluck, P. Bouillet, M. J. Herold, D. H. D. Gray, D. C. S. Huang, M. F. van Delft and G. Dewson, VDAC2 enables BAX to mediate apoptosis and limit tumor development, Nat. Commun. 9(1) (2018) Article ID 4976 (13 pages); https://doi.org/10.1038/s41467-018-07309-4
  25. H. Xian and Y. C. Liou, Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy, Autophagy 15(12) (2019) 2107–2125; https://doi.org/10.1080/15548627.2019.1596494
  26. L. Bai, H. M. Ni, X. Chen, D. DiFrancesca and X. M. Yin, Deletion of Bid impedes cell proliferation and hepatic carcinogenesis, Am. J. Pathol. 166(5) (2005) 1523–1532; https://doi.org/10.1016/s0002-9440(10)62368-1
  27. A. Wree, C. D. Johnson, J. Font-Burgada, A. Eguchi, D. Povero, M. Karin and A. E. Feldstein, Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation, Cell Death Differ. 22(12) (2015) 1985–1994; https://doi.org/10.1038/cdd.2015.46
  28. M. J. Morgan and Z. G. Liu, Crosstalk of reactive oxygen species and NF-κB signaling, Cell Res. 21(1) (2011) 103–115; https://doi.org/10.1038/cr.2010.178
  29. C. Yu, S. Yan, B. Khambu, X. Chen, Z. Dong, J. Luo, G. K. Michalopoulos, S. Wu and X. M. Yin, Gene expression analysis indicates divergent mechanisms in DEN-induced carcinogenesis in wild type and Bid-deficient livers, PLoS One 11(5) (2016) e0155211; https://doi.org/10.1371/journal.pone.0155211
  30. S. H. Moon, C. H. Huang, S. L. Houlihan, K. Regunath, W. A. Freed-Pastor, J. P. t. Morris, D. F. Tschaharganeh, E. R. Kastenhuber, A. M. Barsotti, R. Culp-Hill, W. Xue, Y. J. Ho, T. Baslan, X. Li, A. Mayle, E. de Stanchina, L. Zender, D. R. Tong, A. D’Alessandro, S. W. Lowe and C. Prives, p53 represses the mevalonate pathway to mediate tumor suppression, Cell 176(3) (2019) 564–580; https://doi.org/10.1016/j.cell.2018.11.011
  31. D. Reddy, R. Kumavath, P. Ghosh and D. Barh, Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways, Biomolecules 9(12) (2019) Article ID 792 (20 pages); https://doi.org/10.3390/biom9120792
  32. W. Hao, S. Wang and Z. Zhou, Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway, Int. J. Clin. Exp. Pathol. 8(10) (2015) 12075–12083.
  33. X. B. Jia, Q. Zhang, L. Xu, W. J. Yao and L. Wei, Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway, Biol. Res. 54(1) (2021) Article ID 7 (15 pages); https://doi.org/10.1186/s40659-021-00330-w
  34. T. Otto and P. Sicinski, Cell cycle proteins as promising targets in cancer therapy, Nat. Rev. Cancer 17(2) (2017) 93–115; https://doi.org/10.1038/nrc.2016.138
  35. Y. Hu, K. Yu, G. Wang, D. Zhang, C. Shi, Y. Ding, D. Hong, D. Zhang, H. He, L. Sun, J. N. Zheng, S. Sun and F. Qian, Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell, Biochem. Pharmacol. 150 (2018) 280–292; https://doi.org/10.1016/j.bcp.2018.02.023
  36. M. Rasheduzzaman, H. Yin and S. Y. Park, Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation, Mol. Carcinog. 58(11) (2019) 2040–2051; https://doi.org/10.1002/mc.23096
  37. I. Durmaz, E. B. Guven, T. Ersahin, M. Ozturk, I. Calis and R. Cetin-Atalay, Liver cancer cells are sensitive to lanatoside C induced cell death independent of their PTEN status, Phytomedicine 23(1) (2016) 42–51; https://doi.org/10.1016/j.phymed.2015.11.012
  38. A. Rauf, T. Abu-Izneid, A. A. Khalil, M. Imran, Z. A. Shah, T. B. Emran, S. Mitra, Z. Khan, F. A. Alhu maydhi, A. S. M. Aljohani, I. Khan, M. M. Rahman, P. Jeandet and T. A. Gondal, Berberine as a potential anticancer agent: A comprehensive review, Molecules 26(23) (2021) Article ID 7368 (19 pages); https://doi.org/10.3390/molecules26237368+
  39. D. Bertheloot, E. Latz and B. S. Franklin, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, Cell. Mol. Immunol. 18(5) (2021) 1106–1121; https://doi.org/10.1038/s41423-020-00630-3
  40. D. E. Hong, J. E. Yu, J. W. Lee, D. J. Son, H. P. Lee, Y. Kim, J. Y. Chang, D. W. Lee, W. K. Lee, J. Yun, S. B. Han, B. Y. Hwang and J. T. Hong, A natural CHI3L1-targeting compound, ebractenoid f, inhibits lung cancer cell growth and migration and induces apoptosis by blocking CHI3L1/AKT signals, Molecules 28(1) (2022) Article ID 329 (16 pages); https://doi.org/10.3390/molecules28010329
DOI: https://doi.org/10.2478/acph-2024-0006 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 149 - 164
Accepted on: Feb 13, 2024
Published on: Mar 30, 2024
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2024 Zongyi Shen, Liqi Yin, Manxia Chang, Haifeng Wang, Mingxuan Hao, Youfeng Liang, Rui Guo, Ying Bi, Jiansong Wang, Changyuan Yu, Jinmei Li, Qiongli Zhai, Runfen Cheng, Jinku Zhang, Jirui Sun, Zhao Yang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.